CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd and focused on biosimilars, today announces that it has entered into a marketing and distribution agreement with a leading European healthcare and pharmaceuticals company STADA Arzneimittel AG.

Under the terms of the agreement, STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories, including France and Germany. New brand names will be created and registered for each biosimilar.

This agreement is expected to expand CuraTeQ's market reach, drive revenue growth, and leverage STADA's established distribution network in EU markets.